Pilgrim T, Rothenbühler M, Siontis GCM, et al. - Researchers compared ultrathin strut, biodegradable polymer sirolimus eluting stents (BP SES) vs thin strut, durable polymer everolimus-eluting stents (DP EES), in terms of safety and efficacy in patients receiving percutaneous coronary intervention (PCI). From five randomized trials with 5,780 patients, individual participant data were pooled. A one-stage meta-analysis was conducted applying a mixed effects Cox regression model. The median span of follow-up was 739 days. Occurrence of target-lesion failure in 337 (10.3%) and 304 (12.2%) patients managed with BP SES and DP EES was reported. In terms of cardiac death, target-vessel myocardial infarction, and clinically-driven target-lesion revascularization, no significant differences were found between BP SES and DP EES. Across major subgroups, the impact was consistent. Overall, findings revealed a similar risk of target-lesion failure with BP SES vs DP EES in patients receiving PCI.